Tirzepatide
Also known as: LY3298176
A dual GIP/GLP-1 receptor agonist studied across a large metabolic clinical-trial programme.
Overview
Tirzepatide is a dual agonist engaging both GIP and GLP-1 receptors, positioned in research between single GLP-1 agonists and the newer triple agonists.
How it’s studied to work
Simultaneous GIP and GLP-1 receptor activation is studied for complementary effects on insulin response, appetite, and energy handling.
Research areas
- ›Dual-incretin pharmacology
- ›Glucose and body-weight research
- ›Comparative metabolic studies
Further reading
Links open external literature databases. Citations are curated starting points, not an exhaustive or endorsing list.
For laboratory and research use only. Not a drug, supplement, or medical device. This page is educational and is not medical advice; nothing here describes a product intended for human or veterinary use.